Radiolabeling Process for PSMA Compounds via Acidic Oxidation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing radiolabeled compounds targeting prostate-specific membrane antigen (PSMA) for prostate cancer imaging and therapy have low radiochemical yield and reduced binding, necessitating the development of improved processes for efficient radiolabeling and purification.
Innovation Solution
The process involves reacting a compound of formula (II) with a metal salt of iodine in the presence of an oxidant under acidic conditions, with specific pH control and the addition of a low concentration of cold metal iodide, followed by chromatographic purification, to achieve high radiochemical yield and stability of the radiolabeled compound.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current methods are used for producing radiolabeled compounds, then the production process is simple, but the radiochemical yield is low and binding is reduced
Solution Approach 1:
The patent applies parameter changes by optimizing pH control (maintaining acidic conditions), adjusting oxidant concentration and type, controlling reaction temperature, and regulating the addition rate of reagents. These parameter optimizations directly increase radiochemical yield from low levels to greater than 75% while managing process complexity through systematic control
Solution Approach 2:
The patent uses an oxidant as an intermediary substance to facilitate the radiolabeling reaction between the compound of formula (II) and metal salt of iodine. The oxidant mediates the transformation by enabling the formation of the radiolabeled compound while allowing for controlled reaction conditions that improve yield without excessive complexity
2Quantity of substance
If radiolabeled compounds are produced with higher yield, then more material is available for imaging and therapy, but the production process becomes more complex
Solution Approach 1:
The patent employs preliminary action by preparing the compound of formula (II) in advance with appropriate functional groups positioned for radiolabeling. The precursor compound is synthesized and purified before the actual radiolabeling step, allowing the radioactive reaction to proceed efficiently with high yield while keeping the overall manufacturing process organized and manageable
Solution Approach 2:
The patent maintains continuity of useful action through optimized reaction conditions that ensure continuous formation of the radiolabeled compound throughout the reaction period. By controlling pH, temperature, and reagent addition to sustain optimal reaction conditions, the process maximizes the quantity of product formed without requiring complex intermittent interventions
3Productivity
If radiochemical yield is increased to greater than 75%, then the effectiveness for imaging and therapy improves, but the reaction conditions become more stringent
Solution Approach 1:
The patent implements feedback control by monitoring pH levels throughout the reaction and adjusting acid or base addition accordingly to maintain optimal acidic conditions. This feedback mechanism ensures that the stringent pH requirements for achieving greater than 75% radiochemical yield are continuously met without requiring excessive manual intervention or complex automation
Solution Approach 2:
The patent applies partial or excessive action by using an excess of oxidant relative to the stoichiometric requirements. This ensures that the radiolabeling reaction proceeds to completion with high yield, compensating for any losses or side reactions, while the excess oxidant can be easily removed or neutralized in the workup procedure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the radiochemical yield to greater than 75% and ensures the stability and specificity of the radiolabeled compound, enhancing its potential for both imaging and therapeutic applications in prostate cancer.
Implementation Method 1
reacting a compound of formula (II) with a metal salt of *I in the presence of an oxidant under acidic condition
Data Source
AI summary
A manufacturing process for the preparation of radiolabeled compounds of formula (I)includes reacting compounds of formula (II) with a source of readionuclide of a halogen in the presence of an oxidant under acidic condition,wherein:*I is 123I, 124I, 125I or 131I;R is lower alkyl, optionally substituted with one or more fluorine atoms;Q is C(O), O, NR′, S, S(O)2, C(O)2, (CH2)p;Y is C(O), O, NR′, S, S(O)2, C(O)2, (CH2)p;R′ is H, C(O), S(O)2, C(O)2;Z is H, C1-C4 alkyl, benzyl, substituted benzyl or trialkylsilyl;m is 0, 1, 2, 3, 4 or 5;n is 0, 1, 2, 3, 4, 5 or 6; andp is 0, 1, 2, 3, 4, 5 or 6.